TAK1 inhibition subverts the osteoclastogenic action of TRAIL while potentiating its antimyeloma effects

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) agonists induce tumor-specific apoptosis indicating that they may be an attractive therapeutic strategy against cancers, including multiple myeloma (MM). Osteoclastogenesis is highly induced in MM, which in turn enhances MM growth, ther...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Tenshin, Hirofumi, Teramachi, Jumpei, Oda, Asuka, Amachi, Ryota, Hiasa, Masahiro, Bat-Erdene, Ariunzaya, Watanabe, Keiichiro, Iwasa, Masami, Harada, Takeshi, Fujii, Shiro, Kagawa, Kumiko, Sogabe, Kimiko, Nakamura, Shingen, Miki, Hirokazu, Kurahashi, Kiyoe, Yoshida, Sumiko, Aihara, Kenichi, Endo, Itsuro, Tanaka, Eiji, Matsumoto, Toshio, Abe, Masahiro
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Immunobiology and Immunotherapy
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737122/
https://ncbi.nlm.nih.gov/pubmed/29296860
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2017008813
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados